Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP7 | P09237 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP14 | P50281 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590175 | 0.85 | DRD2 (0.41) | GLANPSR1 | |
| SCHEMBL4373385 | 0.76 | ELANE (0.39) | ALDH1A1KDM4EGAAHPGDNPSR1 | |
| SCHEMBL3585383 | 0.74 | LMNA (0.37) | ALDH1A1KDM4EGAAMMP2MMP9 | |
| SCHEMBL4365447 | 0.74 | POLB (0.44) | ALDH1A1KDM4EGAANPSR1 | |
| SCHEMBL8592625 | 0.74 | CA2 (0.43) | ALDH1A1KDM4EHPGDCA2 | |
| SCHEMBL26354502 | 0.72 | ALDH1A1 (0.40) | ALDH1A1KDM4EGAAHPGDNPSR1 | |
| SCHEMBL11897875 | 0.71 | GLA (0.31) | GLANPSR1 | |
| SCHEMBL8974400 | 0.71 | BACE1 (0.52) | — | |
| SCHEMBL575589 | 0.69 | CA2 (0.52) | ALDH1A1KDM4EGAAHPGDMMP2 | |
| SCHEMBL82815 | 0.66 | MMP2 (0.44) | ALDH1A1KDM4EGAAHPGDMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222013-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12285436-B2 | Substituted pyridines as DNMT1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-29 | — | — | US | disclosed |
| US-20240180933-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| EP-4301733-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | GlaxoSmith Kline Intellectual Property Development Limited (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | GlaxoSmith Kline Intellectual Property Development Limited (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | GlaxoSmith Kline Intellectual Property Development Limited (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20230101987-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| WO-2022185160-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180933-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | DNMT1, DNMT3A, DNMT3B | ALDH1A1 411/4885KDM4E 135/4885GAA 778/4885 |
| US-20230101987-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | DNMT1, DNMT3A, DNMT3B | ALDH1A1 411/4885KDM4E 135/4885GAA 778/4885 |
| US-11771711-B2 | Substituted pyridines as DNMT1 inhibitors | DNMT1, DNMT3A, DNMT3B | ALDH1A1 411/4885KDM4E 135/4885GAA 778/4885 |
| US-20250222013-A1 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | DNMT1, DNMT3A, DNMT3B | ALDH1A1 411/4885KDM4E 135/4885GAA 778/4885 |
| US-12285436-B2 | Substituted pyridines as DNMT1 inhibitors | DNMT1, DNMT3A, DNMT3B | ALDH1A1 411/4885KDM4E 135/4885GAA 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.